{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:26:18Z","timestamp":1792664778540,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T00:00:00Z","timestamp":1537574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T00:00:00Z","timestamp":1537574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00198-018-4687-2","type":"journal-article","created":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T22:58:36Z","timestamp":1537570716000},"page":"71-78","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies"],"prefix":"10.1007","volume":"30","author":[{"given":"D. L.","family":"Kendler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Chines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. L.","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Papapoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. M.","family":"Lewiecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-Y.","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mu\u00f1oz Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. G.","family":"Bone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,22]]},"reference":[{"issue":"9041","key":"4687_CR1","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348(9041):1535\u20131541","journal-title":"Lancet"},{"issue":"2","key":"4687_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jbmr.1494","volume":"27","author":"DM Black","year":"2012","unstructured":"Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RLM, Tan M, Ruzycky ME, Su G, Eastell R (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27(2):243\u2013254","journal-title":"J Bone Miner Res"},{"issue":"12","key":"4687_CR3","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1359\/jbmr.080710","volume":"23","author":"SL Silverman","year":"2008","unstructured":"Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 23(12):1923\u20131934","journal-title":"J Bone Miner Res"},{"issue":"8","key":"4687_CR4","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756\u2013765","journal-title":"N Engl J Med"},{"issue":"4","key":"4687_CR5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1359\/jbmr.2000.15.4.721","volume":"15","author":"CM Klotzbuecher","year":"2000","unstructured":"Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15(4):721\u2013739","journal-title":"J Bone Miner Res"},{"issue":"2","key":"4687_CR6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","volume":"35","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35(2):375\u2013382","journal-title":"Bone"},{"issue":"9395","key":"4687_CR7","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","volume":"362","author":"F Turnbull","year":"2003","unstructured":"Turnbull F (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362(9395):1527\u20131535","journal-title":"Lancet"},{"issue":"4","key":"4687_CR8","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.jacl.2016.04.013","volume":"10","author":"PB Duell","year":"2016","unstructured":"Duell PB, Santos RD, Kirwan BA, Witztum JL, Tsimikas S, Kastelein JJP (2016) Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. J Clin Lipidol 10(4):1011\u20131021","journal-title":"J Clin Lipidol"},{"issue":"11","key":"4687_CR9","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s00198-008-0659-2","volume":"19","author":"A Diez-Perez","year":"2008","unstructured":"Diez-Perez A, Gonzalez-Macias J (2008) Inadequate responders to osteoporosis treatment: proposal for an operational definition. Osteoporos Int 19(11):1511\u20131516","journal-title":"Osteoporos Int"},{"issue":"4","key":"4687_CR10","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/jbmr.1496","volume":"27","author":"A Diez-Perez","year":"2012","unstructured":"Diez-Perez A, Olmos JM, Nogues X, Sosa M, Diaz-Curiel M, Perez-Castrillon JL et al (2012) Risk factors for prediction of inadequate response to antiresorptives. J Bone Miner Res 27(4):817\u2013824","journal-title":"J Bone Miner Res"},{"issue":"12","key":"4687_CR11","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1007\/s00198-012-2093-8","volume":"23","author":"A Diez-Perez","year":"2012","unstructured":"Diez-Perez A, Adachi JD, Agnusdei D, Bilezikian JP, Compston JE, Cummings SR et al (2012) Treatment failure in osteoporosis. Osteoporos Int 23(12):2769\u20132774","journal-title":"Osteoporos Int"},{"issue":"3","key":"4687_CR12","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/jbmr.1479","volume":"27","author":"S Papapoulos","year":"2012","unstructured":"Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwinski E et al (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM Extension. J Bone Miner Res 27(3):694\u2013701","journal-title":"J Bone Miner Res"},{"issue":"11","key":"4687_CR13","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1210\/jc.2013-1597","volume":"98","author":"HG Bone","year":"2013","unstructured":"Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA et al (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM Extension. J Clin Endocrinol Metab 98(11):4483\u20134492","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"4687_CR14","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1007\/s00198-015-3179-x","volume":"26","author":"S Ferrari","year":"2015","unstructured":"Ferrari S, Adachi JD, Lippuner K, Zapalowski C, Miller PD, Reginster JY, T\u00f6rring O, Kendler DL, Daizadeh NS, Wang A, O\u2019Malley CD, Wagman RB, Libanati C, Lewiecki EM (2015) Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Osteoporos Int 26(12):2763\u20132771","journal-title":"Osteoporos Int"},{"issue":"12","key":"4687_CR15","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","volume":"26","author":"S Papapoulos","year":"2015","unstructured":"Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM et al (2015) The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int 26(12):2773\u20132783","journal-title":"Osteoporos Int"},{"issue":"7","key":"4687_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwi\u0144ski E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5(7):513\u2013523","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"4687_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/jbmr.536","volume":"27","author":"MR McClung","year":"2012","unstructured":"McClung MR, Boonen S, Torring O, Roux C, Rizzoli R, Bone HG et al (2012) Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res 27(1):211\u2013218","journal-title":"J Bone Miner Res"},{"key":"4687_CR18","doi-asserted-by":"crossref","unstructured":"Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, Roux C, T\u00f6rring O, Valter I, Wang AT, Brown JP (2018) Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res 33(2):190-198","DOI":"10.1002\/jbmr.3337"},{"issue":"4","key":"4687_CR19","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/jbmr.1808","volume":"28","author":"JP Brown","year":"2013","unstructured":"Brown JP, Roux C, Torring O, Ho PR, Beck Jensen JE, Gilchrist N et al (2013) Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. J Bone Miner Res 28(4):746\u2013752","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-018-4687-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-018-4687-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-018-4687-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T10:05:47Z","timestamp":1591697147000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-018-4687-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,22]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["4687"],"URL":"https:\/\/doi.org\/10.1007\/s00198-018-4687-2","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,22]]},"assertion":[{"value":"1 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DL Kendler: Received research grants from Amgen Inc., Eli Lilly, Astellas, and AstraZeneca; consulting fees from Amgen Inc. and Eli Lilly; and honoraria from Amgen Inc., Pfizer, Eli Lilly, and Merck.A Chines and A Wang: Employees of and stockholders in Amgen Inc.ML Brandi: Received honoraria from Amgen, Bruno Farmaceutici, and Kyowa Kirin; received academic grants and\/or was a speaker for Abiogen, Alexion, Amgen, Bruno Farmaceutici, Eli Lilly, Kyowa Kirin, MSD, NPS, Servier, Shire, and SPA; served as a consultant to Alexion, Bruno Farmaceutici, Kyowa Kirin, Servier, and Shire.S Papapoulos: Received consulting fees or lecture fees as an advisory group member or speaker from Amgen Inc. and Merck & Co. Received consulting fees as an ad hoc consultant from Axsome, Gador, and UCB. Received consulting fees as an advisory group member from Radius Health. Received speaking fees from Teva.EM Lewiecki: Received consulting fees or grants as a member of a medical advisory board or study investigator from\/for Amgen Inc., Merck & Co., Eli Lilly, and Radius.J-Y Reginster: Received consulting fees or paid advisory boards from IBSA-Genevrier, Mylan, Radius Health, and Pierre Fabre. Received lecture fees when speaking at the invitation of sponsor from IBSA-Genevrier, Mylan, Cniel, and Dairy Research Council (DRC). Received grant support (all through institution) from IBSA-Genevrier, Mylan, Cniel, and Radius Health.M Mu\u00f1oz Torres: Received lecture fees from Lilly and consulting fees as a member of a medical advisory board member from Amgen Inc.HG Bone: Received consulting fees from Amgen Inc., Merck, Radius, and Shire. Received lecture fees from Amgen Inc. and Shire. Received research grants as an investigator from Amgen Inc., Merck, and Shire. Received fees as a data safety monitoring board member from Grunenthal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}